Black Diamond director granted 6,801 shares

Available on EDGAR 09/21/2026 - 05:30 PM EDT Accepted by SEC EDGAR 09/21/2026 - 05:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Black Diamond Therapeutics, Inc. (BDTX) reported that director Raman Prakash acquired 6,801 shares of common stock on September 18, 2026 as a grant under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy, received in lieu of cash compensation, at a reference price of $1.93 per share based on the September 17, 2026 closing price. Following this equity award, Prakash directly holds 51,840 shares of Black Diamond Therapeutics common stock, and no Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Grant/Award: 6,801 shares

Grant/Award 1 txn

Insider Raman Prakash

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	6,801	$1.93	$13K

Holdings After Transaction: Common Stock — 51,840 shares (Direct)

Holdings Before and After: Common Stock, 45,039 to 51,840 shares (Direct)

Footnotes (2)

1. F1. These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
2. F2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026.

Key Figures

Shares acquired: 6,801 shares Reference price per share: $1.93 per share Holdings after transaction: 51,840 shares +1 more

4 metrics

Shares acquired 6,801 shares Grant of common stock to director on September 18, 2026

Reference price per share $1.93 per share Based on closing market price on September 17, 2026

Holdings after transaction 51,840 shares Director Raman Prakash’s direct ownership after the grant

Shares received in lieu of cash 6,801 shares Equity issued instead of cash compensation under director policy

Key Terms

Sixth Amended and Restated Non-Employee Director Compensation Policy, in lieu of cash compensation, closing market price

3 terms

Sixth Amended and Restated Non-Employee Director Compensation Policy financial

"These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy"

in lieu of cash compensation financial

"elected to receive shares of the Issuer's common stock in lieu of cash compensation"

closing market price financial

"The price reported in Column 4 is based upon the closing market price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BDTX disclose for director Raman Prakash?

BDTX disclosed that director Raman Prakash received a grant of 6,801 shares of common stock on September 18, 2026 as equity compensation in lieu of cash under the company’s non-employee director compensation policy.

How many BDTX shares does director Raman Prakash hold after this Form 4 transaction?

After the reported transaction, director Raman Prakash directly holds 51,840 shares of Black Diamond Therapeutics common stock, as stated in the Form 4 filing.

What was the reference price for the 6,801 BDTX shares granted to the director?

The Form 4 states a price of $1.93 per share, based on the closing market price of Black Diamond Therapeutics common stock on September 17, 2026.

Was the BDTX insider transaction made under a Rule 10b5-1 trading plan?

No. The filing indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating that the September 18, 2026 equity grant to Raman Prakash was made under a Rule 10b5-1 trading plan.

Why did the BDTX director receive shares instead of cash?

According to the Form 4 footnote, the 6,801 shares were issued under Black Diamond Therapeutics’ Sixth Amended and Restored Non-Employee Director Compensation Policy, under which the director elected to receive common stock in lieu of cash compensation for annual services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raman Prakash

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

245 FIRST STREET, 18TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/18/2026		A(1)		6,801	A	$1.93(2)	51,840	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026.

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)